blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4103179

EP4103179 - COMBINATION THERAPY FOR TREATING AMYOTROPHIC LATERAL USING PRIDOPIDINE AND ANOTHER ACTIVE AGENT [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  18.11.2022
Database last updated on 10.07.2024
FormerThe international publication has been made
Status updated on  20.08.2021
Most recent event   Tooltip10.02.2024Supplementary search reportpublished on 13.03.2024  [2024/11]
Applicant(s)For all designated states
Prilenia Neurotherapeutics Ltd.
10 HaMenofim Street
4672561 Herzliya / IL
[2022/51]
Inventor(s)01 / GEVA, Michal
Rozmarin 5, P.O. Box 7253
0000 Even-Yehuda / IL
02 / HAYDEN, Michael
c/o Prilenia Neurotherapeutics Ltd., Mindspace
Offices, Suite 318, HaMenofim 10
4672561 Herzliya / IL
 [2022/51]
Representative(s)Pearl Cohen Zedek Latzer Baratz UK LLP
The Gridiron Building
One Pancras Square
London N1C 4AG / GB
[2022/51]
Application number, filing date21753474.213.02.2021
[2022/51]
WO2021IL50172
Priority number, dateUS20201678956413.02.2020         Original published format: US202016789564
US20201707606921.10.2020         Original published format: US202017076069
[2022/51]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021161319
Date:19.08.2021
Language:EN
[2021/33]
Type: A1 Application with search report 
No.:EP4103179
Date:21.12.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 19.08.2021 takes the place of the publication of the European patent application.
[2022/51]
Search report(s)International search report - published on:IL19.08.2021
(Supplementary) European search report - dispatched on:EP09.02.2024
ClassificationIPC:A61K31/451, A61K31/192, A61K31/575, A61K38/12, A61K31/517, A61K33/242, A61K31/7016, A61K31/437, A61K31/519, A61K39/00, A61P21/00, A61P25/28
[2024/11]
CPC:
A61K31/575 (EP,IL); A61K31/192 (EP,IL); A61K31/437 (EP,IL);
A61K31/451 (EP,IL); A61K31/519 (EP,IL); A61K33/242 (EP,IL);
A61K38/12 (EP,IL); A61P21/00 (EP,IL); A61P25/28 (EP,IL) (-)
C-Set:
A61K31/192, A61K2300/00 (EP);
A61K31/437, A61K2300/00 (EP);
A61K31/451, A61K2300/00 (EP);
A61K31/519, A61K2300/00 (EP);
A61K31/575, A61K2300/00 (EP);
A61K33/242, A61K2300/00 (EP);
A61K38/12, A61K2300/00 (EP)
(-)
Former IPC [2022/51]A61K31/451, A61K31/192, A61K31/575, A61K38/12, A61K31/517, A61K33/242, A61K31/7016, A61K39/00, A61P21/00, A61P25/28
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/51]
TitleGerman:KOMBINATIONSTHERAPIE ZUM BEHANDELN VON AMYOTROPHER LATERALSKLEROSE UNTER VERWENDUNG VON PRIDOIDIN UND EINEM ANDEREN WIRKSTOFF[2022/51]
English:COMBINATION THERAPY FOR TREATING AMYOTROPHIC LATERAL USING PRIDOPIDINE AND ANOTHER ACTIVE AGENT[2022/51]
French:POLYTHÉRAPIE POUR LE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE À L'AIDE DE PRIDOPIDINE ET D'UN AUTRE AGENT ACTIF[2022/51]
Entry into regional phase31.08.2022National basic fee paid 
31.08.2022Search fee paid 
31.08.2022Designation fee(s) paid 
31.08.2022Examination fee paid 
Examination procedure31.08.2022Amendment by applicant (claims and/or description)
31.08.2022Examination requested  [2022/51]
Fees paidRenewal fee
31.08.2022Renewal fee patent year 03
03.01.2024Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]WO2015001379  (BRUSCHETTINI SRL [IT]) [Y] 1-15 * page 5, paragraph l * * page 6, paragraph l * * page 12, paragraph 4 ** claims 1, 4-7 *;
 [Y]WO2018191786  (IMPLICIT BIOSCIENCE PTY LTD [AU]) [Y] 1-15 * pages 43-46; example 1 * * claims 2, 13, 32, 40, 47 *;
 [Y]WO2019036358  (TEVA PHARMACEUTICALS INT GMBH [CH], et al) [Y] 1-15 * page 8, lines 5-7 * * page 9, lines 20-33 * * page 12, line 15 - page 14, line 7 * * pages 27-33; examples 1-7 * * claims 1, 2, 4-10, 12-16 *;
 [Y]  - IONESCU ARIEL ET AL, "Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1G93A Model", CELL DEATH & DISEASE, vol. 10, no. 210, doi:10.1038/s41419-019-1451-2, (20190301), pages 1 - 19, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397200/pdf/41419_2019_Article_1451.pdf, XP055847053 [Y] 1-15 * abstract * * page 9, column 1, paragraph 2 - column 2, paragraph 1 * * page 9, column 2, paragraph 3 * * page 18, column 1, paragraphs 3-4 *

DOI:   http://dx.doi.org/10.1038/s41419-019-1451-2
International search[A]WO2008133884  (COMBINATORX INC [US], et al) [A] 1-21 * Abstract, tables la, Ib, 2 and 3, claims 1, 7, 15, 20, 39 *;
 [Y]WO2014181333  (BIO BLAST PHARMA LTD [IL]) [Y] 1-10,17-21 * Abstract, page 5 paragraphs 1-2, claims 1, 3 *;
 [Y]WO2019036358  (TEVA PHARMACEUTICALS INT GMBH [CH], et al) [Y] 1-21 * Abstract, page 9 lines 20-33, page 12 line 15 - page 14 line 7, page 22, pages 27-33, figures, claims *;
 [Y]  - Ionescu Ariel, Gradus Tal, Altman Topaz, Maimon Roy, Saraf Avraham Noi, Geva Michal, Hayden Michael, Perlson Eran, "Targeting the Sigma-1 receptor via pridopidine ameliorates central features of ALS pathology in a SOD1G93A model", Cell Death Dis, (20190301), vol. 10, no. 210, doi:10.1038/s41419-019-1451-2, pages 1 - 19, XP055847053 [Y] 1-21 * The whole document *

DOI:   http://dx.doi.org/10.1038/s41419-019-1451-2
 [Y]  - FIGUEIREDO M, "FDA gives OK to HEALEY ALS platform trial testing zilucoplan, CNM- Au8, and verdiperstat", ALS News Today, (20200127), pages 1 - 6, URL: https://alsnewstoday.com/news-posts/2020/01/27/fda-gives-ok-healey-als-platform-trial-testing-first-three-therapies-zilucoplan-cnm-au8-verdiperstat, (20210406), XP055847069 [Y] 1-10,14-21 * The whole docuemnt *
 [Y]  - BIGICA A, "The road to success in ALS: Details of the AMX0035 CENTAUR trial", NeurologyLive, (20191219), pages 1 - 3, URL: https://www.neurologylive.com/view/the-road-to-success-in-als-details-of-the-amx0035-centaur-trial, (20210406), XP055847078 [Y] 1-13,17-21 * The whole document *
 [PY]  - BENDER K, "How an innovative trial design may change the ALS treatment landscape", NeurologyLive, (20200226), pages 1 - 6, URL: https://www.neurologylive.com/view/how-an-innovative-trial-design-may-change-the-als-treatment-landscape, (20210406), XP055847083 [PY] 1-10,14-21 * The whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.